Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Verrica Pharmaceuticals (NASDAQ:VRCA - Free Report) from a sell rating to a hold rating in a research note published on Thursday morning.

Other equities analysts have also issued research reports about the stock. HC Wainwright reissued a "neutral" rating on shares of Verrica Pharmaceuticals in a research report on Tuesday, April 8th. Needham & Company LLC reissued a "hold" rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, May 14th. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Verrica Pharmaceuticals currently has an average rating of "Hold" and an average price target of $8.00.

Verrica Pharmaceuticals Stock Down 2.9%

Shares of NASDAQ:VRCA traded down $0.02 during trading on Thursday, reaching $0.59. The stock had a trading volume of 92,185 shares, compared to its average volume of 581,087. The business has a fifty day moving average price of $0.51 and a 200-day moving average price of $0.67. The stock has a market cap of $54.94 million, a P/E ratio of -0.32 and a beta of 1.73. Verrica Pharmaceuticals has a fifty-two week low of $0.38 and a fifty-two week high of $9.36.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.04. The business had revenue of $3.44 million during the quarter, compared to analyst estimates of $2.53 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. As a group, equities analysts forecast that Verrica Pharmaceuticals will post -1.46 EPS for the current year.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in Verrica Pharmaceuticals by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 477,269 shares of the company's stock worth $334,000 after purchasing an additional 21,789 shares during the last quarter. Barclays PLC increased its position in Verrica Pharmaceuticals by 404.6% during the third quarter. Barclays PLC now owns 31,341 shares of the company's stock worth $45,000 after purchasing an additional 25,130 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Verrica Pharmaceuticals by 23.3% during the first quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company's stock worth $61,000 after purchasing an additional 26,308 shares during the last quarter. Invesco Ltd. increased its position in Verrica Pharmaceuticals by 64.8% during the first quarter. Invesco Ltd. now owns 74,388 shares of the company's stock worth $33,000 after purchasing an additional 29,256 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in Verrica Pharmaceuticals by 306.7% during the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company's stock worth $26,000 after purchasing an additional 44,275 shares during the last quarter. Institutional investors and hedge funds own 42.45% of the company's stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.